Core Insights - Teva Pharmaceutical Industries Ltd. announced the final analysis of the PEARL Phase 4 migraine prevention study, demonstrating that AJOVY (fremanezumab) showed sustained effectiveness over a two-year period in reducing migraine frequency, duration, and severity [1][3] Study Overview - The PEARL study was a 24-month real-world observational study involving 1,140 patients, predominantly female (87.25%), with 33.1% having episodic migraine (EM) and 66.9% chronic migraine (CM) [2][3] - The primary endpoint was a ≥50% reduction in Monthly Migraine Days (MMD) during the first 6 months of treatment, with secondary endpoints including mean change from baseline in MMD and treatment adherence [2] Effectiveness and Adherence - Over 66% of patients with EM and 51.6% with CM achieved the primary endpoint and benefitted from sustained migraine prevention for over 24 months [1][3] - Injection adherence rates remained high at approximately 90%, with over 75% (854 out of 1,129) of participants completing the study duration [1][3] Safety and Tolerability - The final analysis confirmed the favorable long-term safety and tolerability of fremanezumab, consistent with its known safety profile from previous studies [1][3] - The data supports the continued clinical use of fremanezumab for migraine prevention, particularly in populations with high disease impact [1][3] Clinical Implications - The findings underscore the importance of real-world studies in shaping clinical practice and highlight the critical role of CGRP-pathway therapies in improving patient outcomes, especially given that migraine is the second leading cause of disability worldwide [1][3]

NORTH CHICAGO, Ill., June 18, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA® / AQUIPTA®, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month.1 The study met the primary endpoint of treatment discontinuation d ...